skip to main content
Show Results with:

Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy

Ghate, Sameer R.

Current medical research and opinion. Volume 34:Number 12 (2018); pp 2169-2176 -- Informa Healthcare

Online access

  • Title:
    Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy
  • Author: Ghate, Sameer R.;
    Ionescu-Ittu, Raluca;
    Burne, Rebecca;
    Ndife, Briana;
    Laliberté, François;
    Nakasato, Antonio;
    Duh, Mei Sheng
  • Found In: Current medical research and opinion. Volume 34:Number 12 (2018); pp 2169-2176
  • Journal Title: Current medical research and opinion
  • Subjects: Clinical medicine--Periodicals; Therapeutics--Periodicals; Melanoma--Health resources--Dabrafenib--Trametinib--Nivolumab--Pembrolizumab--First-line; Dewey: 615.5
  • Rights: legaldeposit
  • Publication Details: Informa Healthcare
  • Abstract: Abstract:

    Objective:To compare healthcare resource utilization (HRU) between patients with metastatic melanoma (MM) initiated on first-line (1L) combination therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib (D + T; oral) and those initiated on 1 L monotherapy with the anti-PD1 monoclonal antibodies nivolumab or pembrolizumab (N/P; intravenous).

    Methods:Patients with melanoma initiated on D + T or N/P from Q1/2014 to Q2/2016 (defined as 1 L treatment for MM) were identified in the Truven MarketScan database. Entropy balancing was used to reweight the N/P cohort in order to make it comparable to the D + T cohort with respect to the mean and variance of baseline covariates. HRU outcomes during 1 L therapy, reported per patient-year (PPY), were described and compared between the two cohorts post-weighting (i.e. independently of baseline covariates).

    Results:Of the 445 patients included, 202 and 243 were initiated on D + T and N/P, respectively. After weighting, patients initiated on N/P had more outpatient visits for drug administration during 1 L therapy than those initiated on D + T (difference = 18.6 visits PPY [95% CI = 16.0–21.1]). Patients initiated on N/P also had more outpatient office visits for reasons other than drug administration (difference = 8.1 visits PPY [95% CI = 1.9–13.7]). No significant differences were observed for other HRU parameters (i.e. inpatient admissions, inpatient days, and emergency department visits during 1 L therapy).

    Conclusions:HRU during 1 L therapy was generally similar between patients initiated on D + T and N/P. Nonetheless, patients initiated on N/P had more outpatient visits, including more outpatient visits for reasons unrelated to drug administration.


  • Identifier: System Number: LDEAvdc_100091922485.0x000001; Journal ISSN: 0300-7995; 10.1080/03007995.2018.1501351
  • Publication Date: 2018
  • Physical Description: Electronic
  • Shelfmark(s): ELD Digital store

Searching Remote Databases, Please Wait